Brummelkamp Thijn R, Fabius Armida W M, Mullenders Jasper, Madiredjo Mandy, Velds Arno, Kerkhoven Ron M, Bernards René, Beijersbergen Roderick L
Division of Molecular Carcinogenesis and Center for Biomedical Genetics, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands.
Nat Chem Biol. 2006 Apr;2(4):202-6. doi: 10.1038/nchembio774. Epub 2006 Feb 13.
The identification of the cellular targets of small molecules with anticancer activity is crucial to their further development as drug candidates. Here, we present the application of a large-scale RNA interference-based short hairpin RNA (shRNA) barcode screen to gain insight in the mechanism of action of nutlin-3 (1). Nutlin-3 is a small-molecule inhibitor of MDM2, which can activate the p53 pathway. Nutlin-3 shows strong antitumor effects in mice, with surprisingly few side effects on normal tissues. Aside from p53, we here identify 53BP1 as a critical mediator of nutlin-3-induced cytotoxicity. 53BP1 is part of a signaling network induced by DNA damage that is frequently activated in cancer but not in healthy tissues. Our results suggest that nutlin-3's tumor specificity may result from its ability to turn a cancer cell-specific property (activated DNA damage signaling) into a weakness that can be exploited therapeutically.
鉴定具有抗癌活性的小分子的细胞靶点对于其作为候选药物的进一步开发至关重要。在此,我们展示了基于大规模RNA干扰的短发夹RNA(shRNA)条形码筛选的应用,以深入了解nutlin-3(1)的作用机制。Nutlin-3是MDM2的小分子抑制剂,可激活p53通路。Nutlin-3在小鼠中显示出强大的抗肿瘤作用,对正常组织的副作用出奇地少。除了p53,我们在此确定53BP1是nutlin-3诱导的细胞毒性的关键介质。53BP1是由DNA损伤诱导的信号网络的一部分,该网络在癌症中经常被激活,但在健康组织中不被激活。我们的结果表明,nutlin-3的肿瘤特异性可能源于其将癌细胞特异性特性(激活的DNA损伤信号)转化为可用于治疗的弱点的能力。